Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1994;90:61-68

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merlini, P. A.
Right arrow Articles by Rosenberg, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merlini, P. A.
Right arrow Articles by Rosenberg, R. D.

Circulation, Vol 90, 61-68, Copyright © 1994 by American Heart Association


ARTICLES

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

PA Merlini, KA Bauer, L Oltrona, D Ardissino, M Cattaneo, C Belli, PM Mannucci and RD Rosenberg
2nd Division of Cardiology, Ca'Granda Niguarda Hospital, Milan, Italy.

BACKGROUND: The blood coagulation system is activated in the acute phase of unstable angina and acute myocardial infarction. However, it remains unclear whether augmented function of the hemostatic mechanism serves only as a marker of the acute thrombotic episode or whether a hypercoagulable state persists for a prolonged period after clinical stabilization. METHODS AND RESULTS: We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 (F1 + 2) and fibrinopeptide A (FPA) in consecutive patients presenting with unstable angina (n = 81) or acute myocardial infarction (n = 32), respectively. At 6 months, plasma determinations were repeated in patients experiencing an uneventful clinical course (unstable angina, n = 57; myocardial infarction, n = 23). We quantitated the plasma levels of F1 + 2 and FPA in control patients with stable angina (n = 37) or healthy individuals (n = 32) who were matched for age and sex. The median plasma concentrations of F1 + 2 and FPA are significantly higher in patients presenting with unstable angina (F1 + 2, 1.08 nmol/L; FPA, 2.4 nmol/L) or acute myocardial infarction (F1 + 2, 1.27 nmol/L; FPA, 3.55 nmol/L) compared with patients with stable angina (F1 + 2, 0.74 nmol/L; FPA, 1.3 nmol/L; P < .0001) or healthy individuals (F1 + 2, 0.71 nmol/L; FPA, 0.80 nmol/L; P < .0001). At 6 months, the median plasma levels of F1 + 2 in patients exhibiting an uneventful clinical course did not differ from values obtained at admission (unstable angina, 1.26 versus 1.07 nmol/L, P = NS; myocardial infarction, 1.22 versus 1.29 nmol/L, P = NS), whereas the median plasma levels of FPA in the same two subpopulations were significantly reduced (unstable angina, 1.1 versus 2.9 nmol/L, P = .0003; myocardial infarction, 1.1 versus 3.0 nmol/L; P = .0028). CONCLUSIONS: During the acute phase of unstable angina and myocardial infarction, patients exhibit increased coagulation system activity. Over the next 6 months, patients with unstable angina or myocardial infarction experiencing an uneventful clinical course manifest a persistent hypercoagulable state with minimal generation of fibrin.


This article has been cited by other articles:


Home page
StrokeHome page
E. Van De Graaff, M. Dutta, P. Das, E. A. Shry, P. D. Frederick, M. Blaney, D. J. Pasta, and S. R. Steinhubl
Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke With Acute Myocardial Infarction
Stroke, October 1, 2006; 37(10): 2546 - 2551.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. Pleym, V. Videm, A. Wahba, A. Asberg, T. Amundsen, L. Bjella, O. Dale, and R. Stenseth
Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 933 - 940.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xu, Y. Huo, M.-C. Toufektsian, S. I. Ramos, Y. Ma, A. D. Tejani, B. A. French, and Z. Yang
Activated platelets contribute importantly to myocardial reperfusion injury
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H692 - H699.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. B. Rothberg, C. Celestin, L. D. Fiore, E. Lawler, and J. R. Cook
Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit
Ann Intern Med, August 16, 2005; 143(4): 241 - 250.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. L. Furie, R. Rosenberg, J. L. Thompson, K. Bauer, J. P. Mohr, B. Rosner, R. Sciacca, S. Barzegar, B. Thornell, T. Costigan, et al.
Thrombin generation in non-cardioembolic stroke subtypes: The Hemostatic System Activation Study
Neurology, September 14, 2004; 63(5): 777 - 784.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Butenas, T. Orfeo, M. T. Gissel, K. E. Brummel, and K. G. Mann
The Significance of Circulating Factor IXa in Blood
J. Biol. Chem., May 28, 2004; 279(22): 22875 - 22882.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird
Thrombin and Phenotypic Modulation of the Endothelium
Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 41 - 53.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Golino, A. Ravera, M. Ragni, P. Cirillo, O. Piro, and M. Chiariello
Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes
Circulation, December 9, 2003; 108(23): 2864 - 2869.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Rak and J. I. Weitz
Heparin and Angiogenesis: Size Matters!
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1954 - 1955.
[Full Text] [PDF]


Home page
BloodHome page
D. Ardissino, P. A. Merlini, K. A. Bauer, M. Galvani, F. Ottani, F. Franchi, F. Bertocchi, R. D. Rosenberg, and P. M. Mannucci
Coagulation activation and long-term outcome in acute coronary syndromes
Blood, October 15, 2003; 102(8): 2731 - 2735.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
I P Casserly and E J Topol
The primacy of clinical effectiveness for cost effectiveness analysis
Heart, March 1, 2003; 89(3): 249 - 250.
[Full Text] [PDF]


Home page
HeartHome page
M Janzon, L-A Levin, and E Swahn
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
Heart, March 1, 2003; 89(3): 287 - 292.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Mehta and S. Yusuf
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 79S - 88S.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. Hauptmann, A. K. Mohan, M. M. Doody, M. S. Linet, and K. Mabuchi
Mortality from Diseases of the Circulatory System in Radiologic Technologists in the United States
Am. J. Epidemiol., February 1, 2003; 157(3): 239 - 248.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. C. Wong, R. P. Giugliano, and E. M. Antman
Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention
JAMA, January 15, 2003; 289(3): 331 - 342.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
P J Sheridan and D C Crossman
Critical review of unstable angina and non-ST elevation myocardial infarction
Postgrad. Med. J., December 1, 2002; 78(926): 717 - 726.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J.W. Eikelboom, J.I. Weitz, A. Budaj, F. Zhao, I. Copland, P. Maciejewski, M. Johnston, and S. Yusuf
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes
Eur. Heart J., November 2, 2002; 23(22): 1771 - 1779.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Kottke-Marchant, M.C. Bahit, C.B. Granger, P. Zoldhelyi, D. Ardissino, L. Brooks, J.H. Griffin, R.F. Potthoff, F. Van de Werf, R.M. Califf, et al.
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes
Eur. Heart J., August 1, 2002; 23(15): 1202 - 1212.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S.E. Husted, L. Wallentin, B. Lagerqvist, F. Kontny, E. Stahle, and E. Swahn
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization
Eur. Heart J., August 1, 2002; 23(15): 1213 - 1218.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
W. Ageno and A. G.G. Turpie
New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins
Can. Med. Assoc. J., April 1, 2002; 166(7): 919 - 924.
[Full Text] [PDF]


Home page
CirculationHome page
M. A. Brouwer and F. W.A. Verheugt
Oral Anticoagulation for Acute Coronary Syndromes
Circulation, March 19, 2002; 105(11): 1270 - 1274.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters
Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin
J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. I. Weitz and H. R. Buller
Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future
Circulation, February 26, 2002; 105(8): 1004 - 1011.
[Full Text] [PDF]


Home page
CirculationHome page
M. Labinaz, R. Kilaru, K. Pieper, S. P. Marso, M. M. Kitt, M. L. Simoons, R. M. Califf, E. J. Topol, P. W. Armstrong, and R. A. Harrington
Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
Circulation, January 22, 2002; 105(3): 322 - 327.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Savonitto, C. B. Granger, D. Ardissino, L. Gardner, C. Cavallini, M. Galvani, F. Ottani, H. D. White, P. W. Armstrong, E. M. Ohman, et al.
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes
J. Am. Coll. Cardiol., January 2, 2002; 39(1): 22 - 29.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
U. Lockowandt and A. Franco-Cereceda
Off-pump coronary bypass surgery causes less immediate postoperative coronary endothelial dysfunction compared to on-pump coronary bypass surgery
Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1147 - 1151.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
Y. Hasumura, N. Aoki, K. Kawano, M. Homori, A. Maki, Y. Hioki, K. Ishikawa, and H. Yoshino
Platelet-Dependent Thrombin Generation in Patients with Unstable Angina Pectoris
Angiology, December 1, 2001; 52(12): 811 - 818.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Tokunou, T. Ichiki, K. Takeda, Y. Funakoshi, N. Iino, H. Shimokawa, K. Egashira, and A. Takeshita
Thrombin Induces Interleukin-6 Expression Through the cAMP Response Element in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1759 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. G. G. Turpie and E. M. Antman
Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes
Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. M. t. Berg, B. A. Hutten, J. C. Kelder, F. W. A. Verheugt, and H. W. T. Plokker
Oral Anticoagulant Therapy During and After Coronary Angioplasty : The Intensity and Duration of Anticoagulation Are Essential to Reduce Thrombotic Complications
Circulation, April 24, 2001; 103(16): 2042 - 2047.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
F. De Lorenzo, A. Noorani, and V.V. Kakkar
Current trends in the management of thromboembolic events
QJM, April 1, 2001; 94(4): 179 - 185.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
T. J. Tegos, E. Kalodiki, M. M. Sabetai, and A. N. Nicolaides
The Genesis of Atherosclerosis and Risk Factors: A Review
Angiology, February 1, 2001; 52(2): 89 - 98.
[Abstract] [PDF]


Home page
Eur Heart JHome page
K. M. Akkerhuis, K.-L. Neuhaus, R. G. Wilcox, A. Vahanian, J.-L. Boland, J. Hoffmann, T. Baardman, G. Nehmiz, U. Roth, A. P. J. Klootwijk, et al.
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study
Eur. Heart J., December 2, 2000; 21(24): 2042 - 2055.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
J. Figueras, Y. Monasterio, R. M. Lidon, E. Nieto, and J. Soler-Soler
Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2036 - 2043.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
W. Ageno and A. G. Turpie
Therapy of unstable angina with the low molecular weight heparins
Vascular Medicine, November 1, 2000; 5(4): 217 - 223.
[Abstract] [PDF]


Home page
CirculationHome page
A. Sonel, B. M. Sasseen, N. Fineberg, N. Bang, and R. L. Wilensky
Prospective Study Correlating Fibrinopeptide A, Troponin I, Myoglobin, and Myosin Light Chain Levels With Early and Late Ischemic Events in Consecutive Patients Presenting to the Emergency Department With Chest Pain
Circulation, September 5, 2000; 102(10): 1107 - 1113.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. G. Goodman, M. Cohen, F. Bigonzi, E. P. Gurfinkel, D. R. Radley, V. Le Iouer, G. J. Fromell, C. Demers, A. G. G. Turpie, R. M. Califf, et al.
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence study
J. Am. Coll. Cardiol., September 1, 2000; 36(3): 693 - 698.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo
Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology
Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432.
[PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. A. Merlini, D. Ardissino, R. D. Rosenberg, E. Colombi, P. Agricola, L. Oltrona, F. Ottani, M. Galvani, K. A. Bauer, B. Bottasso, et al.
In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris
Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2162 - 2166.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Cote, C. Wolfson, S. Solymoss, A. Mackey, J. R Leclerc, D. Simard, F. Rouah, F. Bourque, and B. Leger
Hemostatic Markers in Patients at Risk of Cerebral Ischemia
Stroke, August 1, 2000; 31(8): 1856 - 1862.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. A. Coulter, C. P. Cannon, K. A. Ault, E. M. Antman, F. Van de Werf, A. A. J. Adgey, C. M. Gibson, R. P. Giugliano, M. A. Mascelli, J. Scherer, et al.
High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14
Circulation, June 13, 2000; 101(23): 2690 - 2695.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. K. Kirklin
Pediatric cardiac transplantation
Ann. Thorac. Surg., May 1, 2000; 69(5): 1627 - 1628.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. J. Teede, B. P. McGrath, J. J. Smolich, E. Malan, D. Kotsopoulos, Y.-L. Liang, and R. E. Peverill
Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis
Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1404 - 1409.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Feng, G. H. Tofler, M. G. Larson, C. J. O’Donnell, I. Lipinska, C. Schmitz, P. A. Sutherland, M. T. Johnstone, J. E. Muller, R. B. D’Agostino, et al.
Factor VII Gene Polymorphism, Factor VII Levels, and Prevalent Cardiovascular Disease : The Framingham Heart Study
Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 593 - 600.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. S. Anand and S. Yusuf
Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis
JAMA, December 1, 1999; 282(21): 2058 - 2067.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. M. Antman, C. H. McCabe, E. P. Gurfinkel, A. G. G. Turpie, P. J. L. M. Bernink, D. Salein, A. Bayes de Luna, K. Fox, J.-M. Lablanche, D. Radley, et al.
Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction : Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial
Circulation, October 12, 1999; 100(15): 1593 - 1601.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. C. Becker, F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1020 - 1027.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
P Moruzzi, S Sarzi-Braga, M Rossi, and M Contini
Sleep apnoea in ischaemic heart disease: differences between acute and chronic coronary syndromes
Heart, September 1, 1999; 82(3): 343 - 347.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Soejima, H. Ogawa, H. Yasue, K. Kaikita, K. Nishiyama, K. Misumi, K. Takazoe, Y. Miyao, M. Yoshimura, K. Kugiyama, et al.
Heightened Tissue Factor Associated With Tissue Factor Pathway Inhibitor and Prognosis in Patients With Unstable Angina
Circulation, June 8, 1999; 99(22): 2908 - 2913.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y.-H. Li, J.-K. Teng, W.-C. Tsai, L.-M. Tsai, L.-J. Lin, H.-R. Guo, and J.-H. Chen
Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction
J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1543 - 1548.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. A. Vorchheimer, J. J. Badimon, and V. Fuster
Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease
JAMA, April 21, 1999; 281(15): 1407 - 1414.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. W. H. M. Verheggen, M. P. M. de Maat, V. M. Cats, F. Haverkate, A. H. Zwinderman, C. Kluft, and A. V. G. Bruschke
Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function
Eur. Heart J., April 2, 1999; 20(8): 567 - 574.
[Abstract] [PDF]


Home page
Eur Heart JHome page
R. Linder, J. Oldgren, N. Egberg, L. Grip, G. Larson, A. Siegbahn, and L. Wallentin
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease
Eur. Heart J., April 1, 1999; 20(7): 506 - 518.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
M. Pahor, M. B. Elam, R. J. Garrison, S. B. Kritchevsky, and W. B. Applegate
Emerging Noninvasive Biochemical Measures to Predict Cardiovascular Risk
Arch Intern Med, February 8, 1999; 159(3): 237 - 245.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. Braunwald
Unstable Angina : An Etiologic Approach to Management
Circulation, November 24, 1998; 98(21): 2219 - 2222.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. A. Halon, M. Y. Flugelman, A. Merdler, H. Rennert, J. Shahla, and B. S. Lewis
Long-term (10-year) outcome in patients with unstable angina pectoris treated by coronary balloon angioplasty
J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1603 - 1609.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Manten, R. J. de Winter, M. C. Minnema, H. ten Cate, J. G. Lijmer, R. Adams, R. J.G. Peters, and S. J.H. van Deventer
Procoagulant and proinflammatory activity in acute coronary syndromes
Cardiovasc Res, November 1, 1998; 40(2): 389 - 395.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. S. Anand, S. Yusuf, J. Pogue, J. I. Weitz, and M. Flather
Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non–Q-Wave Myocardial Infarction : Organization to Assess Str